Nonpeptide ligands for peptidergic G protein-coupled receptors

Advances in Experimental Medicine and Biology

Volumn 692, Issue , 2010, Pages 10-26

  Geary, Timothy G ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; CHOLECYSTOKININ; ENDORPHIN; ENDOTHELIN; ENKEPHALIN; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE; GONADORELIN; LIGAND; MELANOCORTIN; MORPHINE; MOTILIN; NEUROKININ; NEUROPEPTIDE; NEUROPEPTIDE LIGAND; NEUROTENSIN; NEW DRUG; OPIATE; OPIATE PEPTIDE; OXYTOCIN; PEPTIDE; PEPTIDE RECEPTOR; RECEPTOR; RECEPTOR BLOCKING AGENT; SOMATOSTATIN; SUBSTANCE P; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROTENSIN; VASOPRESSIN; DRUG RECEPTOR;

ARTICLE; BASIC RESEARCH; DRUG DEVELOPMENT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; INVERTEBRATE; MAMMAL; MOLECULAR STABILITY; NONHUMAN; PARASITE CONTROL; PEPTIDERGIC NERVOUS SYSTEM; PEST CONTROL; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VERTEBRATE; DRUG EFFECT; GENETICS; PHYSIOLOGY; REVIEW;

INVERTEBRATA; MAMMALIA; VERTEBRATA;

DRUG DISCOVERY; LIGANDS; NEUROPEPTIDES; RECEPTORS, DRUG; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION;

EID: 79952278104     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6902-6_2     Document Type: Article

References (71)

1. Scharrer B. The neuropeptide saga. Amer Zool 1990; 30:887-95
2. Hökfelt T, Broberge C, Xu ZQD et al. Neuropeptides-an overview. Neuropharmacol 2000; 39:1337-56.
3. Strand FL. Neuropeptides: Regulators of Physiological Processes. MIT Press, Cambridge, MA 1999.
4. Hökfelt T, Bartfai T, Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol 2003; 2:463-72. (Pubitemid 36876103)
5. Brain SD, Cox HM. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Brit J Pharmacol 2006; 147:S202-11. (Pubitemid 43077278)
6. Nässel DR. Neuropeptides in the nervous system of Drosophila and other insects: multiple roles as neuromodulators and neurohormones. Prog Neurobiol 2002; 68:1-84. (Pubitemid 35339441)
7. McVeigh P, Kimber MJ, Novozhilova E et al. Neuropeptide signaling systems in flatworms. Parasitol 2005; 131(Suppl):S41-55.
8. McVeigh P, Leech S, Mair GR et al. Analysis of FMRFamide-like peptide (FLP) diversity in phylum Nematoda. Int J Parasitol 2005; 35:1043-60. (Pubitemid 41219713)
9. McVeigh P, Alexander-Bowman S, Veal E et al. Neuropeptide-like protein diversity in phylum Nematoda. Int J Parasitol 2008; 38:1493-503.
10. Masler EP, Kelly TJ, Menn JJ. Insect neuropeptides: discovery and application in insect management. Arch Insect Biochem Physiol 1993; 22:87-111.
11. Gäde G, Goldsworthy GJ. Insect peptide hormones: a selective review of their physiology and potential application for pest control. Pest Man Sci 2003; 59:1063-75.
12. Maule AG, Mousley A, Marks NJ et al. Neuropeptide signaling systems-potential targets for parasite and pest control. Curr Top Med Chem 2002; 2:733-58.
13. Mousley A, Maule AG, Halton DW et al. Inter-phyla studies on neuropeptides: the potential for broad-spectrum anthelmintic and/or endectocide discovery. Parasitol 2005; 131(Suppl):S143-67.
14. Greenwood K, Williams T, Geary T. Nematode neuropeptide receptors and their development as anthelmintic screens. Parasitol 2005; 131:S169-77.
15. Akerlund M. Oxytocin antagonists in the treatment of preterm labour. Fet Matern Med Rev 2002; 13:31-41. (Pubitemid 34288600)
16. Ashworth DM, Bit AR, Baxter AJ et al. Nonpeptide oxytocin agonists. Drugs Future 2006; 31:345-53.
17. Lottmann H, Baydala L, Eggert P et al. Long-term desmopressin response in primary nocturnal enuresis: open-label, multinational study. Int J Clin Pract 2009; 63:35-45.
18. Decaux G, Soupart A, Vassart G. Nonpeptide arginine-vasopressin antagonists: the vaptans. Lancet 2008; 371:1624-32.
19. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148:16-29. (Pubitemid 351664943)
20. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008; 121:656-63.
21. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 2007; 29:2614-34.
22. Knop FK, Vilsboll T, Holst JJ. Incretin-based therapy of type 2 diabetes mellitus. Curr Prot Pept Sci 2009; 10:46-55.
23. Hansen KB, Knop FK, Holst JJ et al. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract 2009; 63:1154-60.
24. Jones RM, Boatman PD, Semple G et al. Clinically validated peptides as templates for de novo peptidomimetic drug design as G-protein-coupled receptors. Curr Opin Pharmacol 2003; 3:530-543. (Pubitemid 37221135)
25. Lingueglia E, Deval E, Lazdunski M. FMRFamide-gated sodium channel and ASIC channels: a new class of ionotropic receptors for FMRFamide and related peptides. Peptides 2006; 27:1138-52.
26. Purcell J, Robertson AP, Thompson DP et al. PF4, a FMRFamide-related peptide, gates low-conductance Cl channels in Ascaris suum. Eur J Pharmacol 2002; 456:11-17. (Pubitemid 35351731)
27. Meeusen T, Mertens I, De Loof A et al. G protein-coupled receptors in invertebrates: a state of the art. Int Rev Cytol 2003; 230:189-261. (Pubitemid 37517866)
28. Claeys I, Poels J, Simonet G et al. Insect neuropeptide and peptide hormone receptors: current knowledge and future directions. Vit Horm 2005; 73:217-86.
29. Hawking F. History of chemotherapy. In: Schnitzer RJ, Hawking F, eds. Experimental Chemotherapy. New York: Academic Press, 1963:1-24.
30. Drews J. Drug discovery: a historical perspective. Science 2000; 287:1960-63
31. Williams M. Receptor binding in the drug discovery process. Med Res Rev 1991; 11:147-184.
32. Kenny BA, Bushfield M, Parry-Smith DJ et al. The application of high-throughput screening to novel lead discovery. Prog Drug Res 1988; 51:245-269.
33. Hughes J, Smith T, Kosterlitz H et al. Isolation of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258:577-9.
34. Janecka A, Fichna J, Janecki T. Opioid receptors and their ligands. Curr Top Med Chem 2004; 4:1-17. (Pubitemid 38842558)
35. Snyder SH, Pasternak GW. Historical review: opioid receptors. Trends Pharmacol Sci 2003; 24:198-205. (Pubitemid 36432108)
36. Chang RSL, Lotti VJ, Monaghan RL et al. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science 1985; 230:177-9. (Pubitemid 16228558)
37. Evans BE, Rittle KE, Bock MG et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988; 31:2235-46. (Pubitemid 19001640)
38. Goldstein A, Lowney LI, Pal BK. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc Natl Acad Sci USA 1971; 68:1742-47.
39. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nature Revs Drug Disc 2006; 5:919-31. (Pubitemid 44660605)
40. Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 2003; 23:559-605. (Pubitemid 37034145)
41. Berna MJ, Tapia JA, Sancho V et al. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol 2007; 7:583-92. (Pubitemid 350177555)
42. Silverman L, Campbell R, Broach JR. New assay technologies for high-throughput screening. Curr Opin Chem Biol 1998; 2:397-403. (Pubitemid 128423245)
43. Pausch MH. G protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery. Trends Biotech 1997; 15:487-94. (Pubitemid 27504846)
44. Dowell SJ, Brown AJ. Yeast assays for G protein-coupled receptors. Receptors Channels 2002; 8:343-52.
45. Thomsen W, Frazer J, Unett D. Functional assays for screening GPCR targets. Curr Opin Biotech 2005; 16:655-65. (Pubitemid 41654645)
46. Wang ZX, Broach JR, Peiper SC. Functional expression of CXCR4 in Saccharomyces cerevisiae in the development of powerful tools for the pharmacological characterization of CXCR4. (2006) Meth Mol Biol 2006; 332:115-27.
47. Berthold M, Bartfai T. Modes of peptide binding in G protein-coupled receptors. Neurochem Res 1997; 22:1023-31. (Pubitemid 27299205)
48. Snider RM, Constantine JW, Lowe JA III et al. A potent nonpeptide antagonist of the Substance P (NK1) receptor. Science 1991; 251:435-7. (Pubitemid 21916907)
49. Gether U, Johansen TE, Snider RM et al. Different binding epitopes on the NK1 receptor for substance P and a nonpeptide antagonist. Nature 1993; 362:345-8. (Pubitemid 23101306)
50. Fong TM, Cascieri MA, Yu H et al. Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. Nature 1993; 362:350-3. (Pubitemid 23101308)
51. Fong TM, Yu H, Strader CD. Molecular basis for the species-selectivity of the Neurokinin-1 receptor antagonists CP-96,345 and RP67580. J Biol Chem 1992; 267:25668-71. (Pubitemid 23013958)
52. Sachais BS, Snider RM, Lowe JA III et al. Molecular basis for the species selectivity of the Substance P antagonist CP-96,345. J Biol Chem 1993; 268:2319-23. (Pubitemid 23057845)
53. Garret C, Carruette A, Fardin V et al. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 1991; 88:10208-12. (Pubitemid 21915804)
54. Beinborn M, Lee YM, McBride EW et al. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for nonpeptide antagonists. Nature 1993; 362:348-50. (Pubitemid 23101307)
55. Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 1995; 68:343-64. (Pubitemid 26020722)
56. Michel MC, Beck-Sickinger A, Cox H et al. XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol Rev 1998; 50:143-50. (Pubitemid 28158845)
57. Sugg EE. Nonpeptide agonists for peptide receptors: lessons from ligands. Ann Rep Med Chem 1997; 32:277-83.
58. Marshall GR. Peptide interactions with G-protein coupled receptors. Biopolymers 2001; 60:246-77. (Pubitemid 34074178)
59. Giannis A, Kolter T. Peptidomimetics for receptor ligands-discovery, development and medical perspectives. Agnew Chem Int Ed Engl 1993; 32:1244-67.
60. Hruby VY, Agnes RS. Conformation-activity relationships of opioid peptides with selective activities at opiate receptors. Biopolymers 1999; 51:391-410. (Pubitemid 30262484)
61. Rashid AJ, O'Dowd BF, George SN. Minireview: Diversity and complexity of signaling through peptidergic G protein-coupled receptors. 2004; Endocrinol 145:2645-52. (Pubitemid 38686210)
62. Freidinger RM. Nonpeptidic ligands for peptide and protein receptors. Curr Opin Chem Biol 1999; 3:395-406. (Pubitemid 29376101)
63. Gurrath M. Peptide-binding G protein-coupled receptors: new opportunities for drug design. Curr Med Chem 2001; 8:1605-48. (Pubitemid 33076805)
64. Estriarte M, Rich D. Peptidomimetics for drug design. In: Abraham DJ, ed. Burger's Medicinal Chemistry and Drug Discovery. Hoboken:Wiley-Interscience 2003:1(6):633-85.
65. Blakeney JS, Reid RC, Le GT et al. Nonpeptidic ligands for peptide-activated G protein-coupled receptors. Chem Rev 2007; 107:2960-3041. (Pubitemid 47189009)
66. Li C, Kim K. Neuropeptides ed. The C. Elegans Research Community. WormBook, doi/10.1895/wormbook.1.7.1, http://www.wormbook.org 2008.
67. Husson SJ, Mertens I, Janssen T et al. Neuropeptidergic signaling in the nematode Caenorhabditis elegans. Prog Neurobiol 2007; 82:33-55. (Pubitemid 46719588)
68. Isaac RE, Bland ND, Shirras AD. Neuropeptidases and the metabolic inactivation of insect neuropeptides. Gen Comp Endocrinol 2009; 162:8-17.
69. Han M, Park D, Vanderzalm PJ et al. Drosophila uses two distinct neuropeptide amidating enzymes, dPAL1 and dPAL2. J Neurochem 2004; 90:129-41. (Pubitemid 38879168)
70. Mair GR, Niciu MJ, Stewart MT et al. A functionally atypical amidating enzyme from the human parasite Schistosoma mansoni. FASEB J 2004; 18:114-21. (Pubitemid 38076471)
71. Peeters T, Matthijs G, Depoortere I et al. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257:G470-4.